Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

Taking stock of the drug industry, from the lab to the medicine chest

June 21, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

JIM LO SCALZO/POOL/AFP via Getty Images STAT+ | Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy Staffers expressed "significant uncertainty" about the benefits of the Elevidys treatment for Duchenne muscular dystrophy, but Marks gave it broad approval. By Jason Mast and Matthew Herper STAT+ | Ginkgo Bioworks lays off 158 employees, with more to come The once fast-growing life sciences firm is slashing expenses amid financial woes. By Jonathan Saltzman — Boston Globe STAT+ | Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments "It's a huge relief," said one advocate. "But the uncertainty and stress of the last six months (was) caused by Vertex's high prices." By Ed Silverman Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser